» Articles » PMID: 8577815

Benzodiazepine Side Effects: Role of Pharmacokinetics and Pharmacodynamics

Overview
Journal Pharmacology
Publisher Karger
Specialty Pharmacology
Date 1995 Oct 1
PMID 8577815
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Benzodiazepines have a wide variety of indications. However, CNS and psychiatric adverse reactions, tolerance, and withdrawal effects of benzodiazepines are becoming increasingly recognized and must be better understood for proper drug use. Certain benzodiazepines are associated with memory impairment and other cognitive defects and hyperexcitability phenomena during treatment (early-morning insomnia, daytime anxiety) and following withdrawal (rebound insomnia and anxiety, seizures). Elimination half-life, receptor-binding affinity, effects on the locus coeruleus-norepinephrine (LC-NE) and hypothalamic-pituitary-adrenal (HPA) axes, and the interaction of these factors appear to be major determinants of frequency and severity of these untoward effects. Rapid drug elimination and high receptor-binding affinity were initially suggested as primary underlying factors which determine frequency, severity, and type of the side effects of benzodiazepines during administration and withdrawal. Newer data and information on triazolobenzodiazepines indicate that these psychiatric adverse reactions also relate to whether the benzodiazepine has strong direct effects on the LC-NE and HPA systems. Initial suppression of the LC-NE and HPA systems is followed, on an interdose basis, by a significant rebound and activation. This repetitive pattern of suppression followed by rebound results in a neurophysiologic and behavioral sensitization (kindling) of the limbic system and consequently contributes to central nervous system and psychiatric adverse reactions. The tendency of certain of these side effects to worsen over time supports empirically this neurophysiologic and biochemical model.

Citing Articles

Dexmedetomidine-associated hypothermia in critical trauma: A case report and literature analysis.

Kim S, Sul Y, Ye J, Lee J, Lee J Medicine (Baltimore). 2025; 104(3):e41349.

PMID: 39833034 PMC: 11749715. DOI: 10.1097/MD.0000000000041349.


Evaluating the safety and efficacy of zuranolone in the management of major depressive disorder and postpartum depression, with or without concurrent insomnia: a rigorous systematic review and meta-analysis.

Raja A, Ahmed S, Siddiqui M, Lamiya Mir S, Kumar R, Ahmed M Front Psychiatry. 2024; 15:1425295.

PMID: 39035602 PMC: 11257908. DOI: 10.3389/fpsyt.2024.1425295.


Positive allosteric adenosine A receptor modulation suppresses insomnia associated with mania- and schizophrenia-like behaviors in mice.

Lin Y, Roy K, Ioka S, Otani R, Amezawa M, Ishikawa Y Front Pharmacol. 2023; 14:1138666.

PMID: 37153764 PMC: 10155833. DOI: 10.3389/fphar.2023.1138666.


Vasovagal Reactions during Interventional Pain Management Procedures-A Review of Pathophysiology, Incidence, Risk Factors, Prevention, and Management.

Malave B, Vrooman B Med Sci (Basel). 2022; 10(3).

PMID: 35893121 PMC: 9332485. DOI: 10.3390/medsci10030039.


First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea.

Noh Y, Lee H, Choi A, Kwon J, Choe S, Chae J PLoS Med. 2022; 19(3):e1003945.

PMID: 35235572 PMC: 8926183. DOI: 10.1371/journal.pmed.1003945.